NanoDx

Executive Summary

NanoDx is a privately held medical device company developing a point-of-care diagnostic platform based on proprietary nano biosensor technology. The platform aims to deliver accurate, real-time test results from a small blood sample within minutes, addressing critical needs in acute care settings. The company's initial focus is on a Traumatic Brain Injury (TBI) test, which could significantly impact emergency medicine by enabling rapid, objective diagnosis. Beyond TBI, NanoDx plans to expand its platform to multiple clinical applications, including infectious diseases, cardiac markers, and therapeutic drug monitoring. The company's technology has the potential to decentralize diagnostics, reducing reliance on central laboratories and expediting clinical decision-making. While still in a private, pre-revenue stage, NanoDx has demonstrated progress through research partnerships and regulatory engagements. The success of the company hinges on receiving FDA clearance for its lead TBI test, establishing commercial partnerships, and demonstrating platform versatility in subsequent indications. Given the early stage, the conviction score is moderate, reflecting both the promising technology and the inherent risks of regulatory and commercial execution.

Upcoming Catalysts (preview)

• Q1 2027FDA 510(k) Clearance for TBI Test60% success
• Q3 2026Publication of Clinical Validation Study Results70% success
• Q4 2026Strategic Partnership for Commercial Distribution50% success